# DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy

> **NCT03369990** · PHASE2 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 98 (estimated)

## Conditions studied

- Benign Masseteric Hypertrophy

## Interventions

- **DRUG:** Botulinum toxin type A
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03369990
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12
- **Primary completion:** 2018-10
- **Final completion:** 2018-10
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2017-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03369990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03369990, "DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03369990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*